ADUS vs MD

ADUS exhibits mixed financial health with a Piotroski F-Score of 4/9, indicating a weak to stable foundation, and no Altman Z-Score available, which limits distress risk assessment. The stock trades at $101.35, below its intrinsic value of $153.99 and Graham Number of $83.83, suggesting potential undervaluation on a defensive basis. However, strong revenue and earnings growth (25.6% and 52.1% YoY) are tempered by bearish insider activity and a lack of dividend. Analysts maintain a 'buy' recommendation with a target of $140.23, reflecting optimism in future performance.

Pediatrix Medical Group (MD) presents a complex profile with a Piotroski F-Score of 4/9, indicating stable but mediocre financial health. While the company is significantly undervalued on a relative basis (P/E 11.50 vs Sector 73.97) and shows a highly attractive PEG ratio of 0.24, these fundamentals are countered by negative revenue growth (-1.70%) and bearish insider activity. The stock is currently trading near its Graham Number ($21.60), suggesting it is fairly valued from a defensive standpoint, despite a much higher growth-based intrinsic value of $46.75.